Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab

Acta Haematologica

Volumn 119, Issue 1, 2008, Pages 48-53

  Sasaki, Makoto ^a   Sugimoto, Koichi ^a   Mori, Takeshi ^a   Karasawa, Kumiko ^a   Oshimi, Kazuo ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alemtuzumab; Hairy cell leukemia variant; Splenic irradiation

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ASPARAGINASE; CLADRIBINE; COMPLEMENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; PENTOSTATIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RADIOTHERAPY; CANCER THERAPY; CASE REPORT; CELL COUNT; CELL DEATH; CELLULAR DISTRIBUTION; CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; MULTIPLE CYCLE TREATMENT; ORGAN SIZE; PRIORITY JOURNAL; RADIATION DOSE; SPLENOMEGALY; TREATMENT FAILURE;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOPROTEINS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, HAIRY CELL; MALE; SPLEEN;

EID: 40549095344     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000115785     Document Type: Article

References (30)

1. Goodman GR, Bethel KJ, Saven A: Hairy cell leukemia: an update. Curr Opin Hematol 2003;10:258-266.
2. Mey U, Strehl J, Gorschlüter M, Ziske C, Glasmacher A, Pralle H, Schmidt-Wolf I: Advances in the treatment of hairy-cell leukemia. Lancet Oncol 2003;4:86-94.
3. Sainati L, Matutes E, Mulligan S, de Oliveria MP, Rani S, Lampert IA, Catovsky D: A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990;76:157-162.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW: Hairy Cell Leukemia. World Health Organization of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 138-141.
5. Matutes E, Wotherspoon A, Catovsky D: The variant form of hairy-cell leukemia. Best Pract Res Clin Haematol 2003;16:41-56.
6. Robak T: Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32:365-376.
7. Narat S, Gandla J, Doqan A, Mehta A: Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 2005;46:1229-1232.
8. Quach H, Januszewicz H, Westerman D: Complete remission of hairy cell leukemia variant (HCl-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 2005;90(suppl):ECR26.
9. Golay J, Manganini M, Rambaldi A, Introna M: Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476-1483.
10. Golay J, Cortiana C, Manganini M, Cazzaniga G, Salvi A, Spinelli O, Bassan R, Barbui T, Biondi A, Rambaldi A, Introna M: The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica 2006;91:322-330.
11. Quigley MM, Bethel KJ, Sharpe RW, Saven A: CD52 expression in hairy cell leukemia. Am J Hematol 2003;74:227-230.
12. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL: Heterogenous CD52 expression among hematologic neoplasms: implication for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-7179.
13. Fietz T, Rieger K, Schmittel A, Thiel E, Knauf W: Alemtuzumab (Campath-1H) in hairy cell leukemia relapsing after rituximab treatment. Hematol J 2004;5:451-452.
14. Rebello P, Hale G: Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002;260:285-302.
15. Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, Hale G, Alexander DR: The CD45 tyrosine phosphate regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol 2000;12:505-516.
16. Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, Schichman SA: Alemtuzumab (CAMPATH-1H) dose not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Lymphoma 2004;28:495-507.
17. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM: Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906-3911.
18. Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ, Lister TA: Loss of CD20 expression following treatment with rituximab (chimeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 2001;114:881-883.
19. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill D: Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 2002;119:412-416.
20. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-7368.
21. Davis TA, Czerwinski DK, Levy R: Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-615.
22. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3354-3361.
23. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, Hillmen P: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971-2979.
24. Fraser G, Smith CA, Imrie K, Meyer R, the Hematology Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care: Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 2007;14:96-109.
25. Sasaki M, Sugimoto K, Kawahara S, Yasuda H, Suto H, Oshimi K: Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia. Eur J Haematol 2007;78:545.
26. Catovsky D, Richards S, Fooks J, Hamblin T: CLL trials in United Kingdom. The Medical Research Council CLL Trials 1,2,3. Leuk Lymphoma 1991;suppl 4:105-112.
27. Sgarabotto D, Vianello F, Radossi P, Poletti A, Sotti G, Stefani PM, Sartori R, Girolami A: Remission in hairy cell leukemia-variant following splenic radiotherapy alone. Leuk Lymphoma 1997;26:395-398.
28. Nishii K, Katayama N, Maeda H, Usui E, Takemitu T, Lorenzo FV, Nakase K, Shiku H: Successful treatment with low-dose splenic irradiation for massive splenomegaly in an elderly patient with hairy-cell leukemia. Eur J Haematol 2001;67:255-257.
29. Williamson TS: Alemtuzumab. Clin J Oncol Nur 2001;5:287-288.
30. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, von Dongen JJ: Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990;136:1215-1222.